Israel’s Therapix Biosciences is conducting a proof-of-concept Phase II clinical study with the Hannover Medical School, of its lead compound THX-TS01 for 20 patients suffering from Tourette Syndrome.

http://www.prnewswire.com/news-releases/therapix-biosciences-and-the-hannover-medical-school-enter-into-an-investigator-initiated-clinical-trial-agreement-to-assess-the-effect-of-txh-ts01-in-patients-with-tourette-syndrome-300453033.html